An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?
Where this comes from
- Record sourced from PubMed, PMID 36797987.
- Also identified by DOI 10.1093/brain/awad049 and PMC identifier 10115350.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical practice will be challenging.
Medical subject headings
- Alzheimer Disease